doi:10.19982/j.issn.1000-6621.20240594

Abstract

CLC Number:

Figures/Tables 4

References 15

[1]	Döffinger R, Helbert MR, Barcenas-Morales G, et al. Autoantibodies to interferon-gamma in a patient with selective susceptibility to mycobacterial infection and organ-specific autoimmunity. Clin Infect Dis, 2004, 38(1):e10-4. doi:10.1086/380453. pmid: 14679469
[2]	Tang BS, Chan JF, Chen M, et al. Disseminated penicilliosis, recurrent bacteremic nontyphoidal salmonellosis, and burkholderiosis associated with acquired immunodeficiency due to autoantibody against gamma interferon. Clin Vaccine Immunol, 2010, 17(7):1132-1138. doi:10.1128/CVI.00053-10.
[3]	Kerner G, Rosain J, Guérin A,et al. Inherited human IFN-γ deficiency underlies mycobacterial disease. J Clin Invest, 2020, 130(6):3158-3171. doi:10.1172/JCI135460. pmid: 32163377
[4]	Yang R, Mele F, Worley L,et al. Human T-bet governs innate and innate-like adaptive IFN-gamma immunity against Mycobacteria. Cell, 2020, 183(7):1826-1847. doi:10.1016/j.cell.2020.10.046. pmid: 33296702
[5]	Qiu Y, Tang M, Zeng W,et al. Clinical findings and predictive factors for positive anti-interferon-γ autoantibodies in patients suffering from a non-tuberculosis mycobacteria or Talaromyces marneffei infection:a multicenter prospective cohort study. Sci Rep, 2022, 12(1):9069. doi:10.1038/s41598-022-13160-x. pmid: 35641599
[6]	Browne SK, Burbelo PD, Chetchotisakd P, et al. Adult-onset immunodeficicency in Thailand and Taiwan. N Engl J Med, 2012, 367(8):725-734. doi:10.1056/NEJMoa1111160.
[7]	Liang S, Liang H, Huang X,et al. Clinical immunological characteristics of anti-interferon-γ autoantibodies syndrome: a 3 year prospective cohort study. Emerg Microbes Infect, 2024, 13(1):2396887. doi:10.1080/22221751.2024.2396887.
[8]	田园, 荆玮, 王庆枫,等. 抗γ干扰素自身抗体阳性耐多药结核病并发马尔尼菲等多重感染一例并文献复习. 中国防痨杂志, 2024, 46(11):1335-1342. doi:10.19982/j.issn.1000-6621.20240212.
[9]	Kiratikanon S, Phinyo P, Rujiwetpongstorn R, et al. Adul-tonset immunodeficiency duetoanti-interferon-gammaautoanti-body-associated Sweet syndrome: A distinctive entity. J Dermatol, 2022, 49(1):133-141. doi:10.1111/1346-8138.16202.
[10]	Su HA, Chen HA, Wang SH,et al. Generalized Pustular Eruptionina Patient with Adult-Onset Immunodeficiency Due to Anti-Interferon-Gamma Autoantibodies. Ann Dermatol, 2023, 35(Suppl 2):S350-S351. doi:10.5021/ad.21.111.
[11]	Hidekawa C, Yoshimi R, Kishimoto D,et al. Anti-interferongamma antibody-seropositive disseminated Nontuberculous mycobacterial infection mimicking POEMS and TAFRO syndromes. Intern Med, 2022, 61(15):2377-2385. doi:10.2169/internalmedicine.8366-21.
[12]	聂永都, 潘思琪, 王瀚,等. 抗干扰素γ自身抗体介导的成人起病免疫缺陷症13例分析. 中华结核和呼吸杂志, 2023, 46(2):144-150. doi:10.3760/cma.j.cn1121147-202220725-00625.
[13]	Zeng W, Tang M, Yang M,et al. Intravenous cyclophosphamide therapy for anti-IFN-gamma autoantibody-associated Talaromyces marneffei infection. Open Forum Infect Dis, 2022, 9(12):c612. doi:10.1093/ofid/ofac612.
[14]	Lee WI, Fang YF, Huang JL,et al. Distinct lymphocyte immunophenotyping and quantitative anti-interferon gamma autoantibodies in Taiwanese of China HIV-negative patients with Non-tuberculous mycobacterial infections. J Clin Immunol, 2023, 43(4):717-727. doi:10.1007/s10875-022-01423-1.
[15]	Tham EH, Huang CH, Soh JY, et al. Neutralizing anti interferon gamma autoantibody levels may not correlate with clinical course of disease. Clin Infect Dis, 2016, 63(4):572-573. doi:10.1093/cid/ciw351.

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 4

References 15

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Tuberculosis Control Branch of Chinese Antituberculosis Association, Standardization Professional Branch of Chinese Antituberculosis Association, Elderly Tuberculosis Control Branch of Chinese Antituberculosis Association. Expert consensus on the application of Mycobacterium tuberculosis infection detection technologies [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 813-829.
[2]	Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis, Beijing Chest Hospital Capital Medlical University/Beijing Tuberculosis and Thoracic Tumor Research Institute. Expert consensus on all-oral short-course therapy for drug-resistant tuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 830-839.
[3]	Wang Jing, Wang Qingfeng, Jing Wei, Wang Yujin, Wang Xueyu, Huang Hairong, Chu Naihui, Nie Wenjuan. Dosage of recombinant Mycobacterium tuberculosis fusion protein for skin testing in the 18-65 year-old population and its safety in the 3-17 and 66-75 year-old populations: a randomized, blinded, positive-controlled phase Ⅱ clinical trial [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 840-845.
[4]	Zhang Canyou, Xia Yinyin, Chen Hui, Zhao Fei, Wang Lixia, Zhang Hui, Cheng Jun. Community-based active case-finding for pulmonary tuberculosis in the elderly: analysis of strategies and effectiveness based on a multicenter cohort study [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 846-854.
[5]	Zhong Yi, Yu Shengnan, Zhang Yuqi, Jing Rui, Li Xiujun. Analysis of public knowledge, attitude and practice on tuberculosis prevention and control based on Structural Equation Modeling [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 855-862.
[6]	Zhou Fangjing, Liang Hongdi, Li Jianwei, Chen Yuhui, Wen Wenpei, Wu Huizhong. Assessment of the public awareness of core information on tuberculosis prevention and control in Guangdong Province based on a two-level model [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 863-869.
[7]	Fan Jiangjing, Zhou Meng, Xu Zuhui, Zhang Chuanfang. Analysis of occupational satisfaction and associated factors among tuberculosis health management staff in primary healthcare institutions in Hunan Province [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 870-877.
[8]	Yang Zeliang, Ma Zichun, Shang Yuanyuan, Shi Jin, Jing Wei, Pang Yu, Qin Lin. The diagnostic value of targeted next generation sequencing in sputum-free pulmonary tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 878-883.
[9]	Zheng Zhuangbin, Bi Lijun, Zhang Liqun. Study on the interaction between Mycobacterium tuberculosis membrane protein MmpS5/MmpL5 and bedaquiline [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 884-892.
[10]	Chen Shuangshuang, Wang Nenhan, Zhao Yanfeng, Fan Ruifang, Tian Lili, Chen Hao, Luo Ping, Li Jie, Li Chuanyou, Dai Xiaowei. Application value of MeltPro two-step method in tuberculosis diagnosis and drug resistance screening [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 893-900.
[11]	Wang Meiji, Liu Meijun, Chen Rui, Xia Lu, Liu Xuhui, Yang Yang, Liu Huarui, Ye Dan, Fei Zhentao, Xie Shiqi, Yang Shuqi, Pan Lei, Zhang Xiaolin, Xu Biao, Li Feng. Functional outcomes and predictors of tuberculous meningitis in children and young adolescents: a hospital-based retrospective study [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 907-913.
[12]	Wei Liuying, Jing Wei, Liu Zhifeng, Nie Wenjuan, Huang Xianzhen, Huang Lianpiao, Ban Fengting, Lin Yanrong, Yang Shixiong, Zhu Qingdong. Cost-effectiveness analysis of bedaquiline-containing regimens for the treatment of patients with multidrug/rifampicin-resistant pulmonary tuberculosis in Nanning: a retrospective cohort study [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 914-920.
[13]	Yu Huimin, Zheng Hui, Liu Eryong, Huang Fei, Wu Dan, Yin Zundong. Research progress on immunization strategies for tuberculosis vaccines [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 930-939.
[14]	Mao Lirong, Nie Yanhui, An Hongjuan, Wang Ruilan, Dong Enjun, Su Yue, Zhao Wenjuan, Du Jingli, An Huiru. Application efficacy and research progress of mass spectrometry detection technology in the diagnosis of osteotuberculosis [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 940-946.
[15]	Wang Yutong, Liu Yuhong, Li Liang. Research progress on psychological and psychiatric adverse reactions induced by antituberculosis drugs [J]. Chinese Journal of Antituberculosis, 2025, 47(7): 947-953.